Ye, Xiang-Yang et al. published their patent in 2018 |CAS: 445490-78-8

The Article related to indazole preparation integrin alpha v antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Name: tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

On May 17, 2018, Ye, Xiang-Yang; Morales, Christian L.; Higgins, Mendi A.; Mull, Eric published a patent.Name: tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate The title of the patent was Indazole derivatives as αV integrin antagonists and their preparation. And the patent contained the following:

The invention provides compounds of formula I or II, or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αV- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathol. fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions Compounds of formula I and II wherein A, E, G and J are independently N,C and NH, with the proviso that at least one of A, E, G and J is C and attached to Y; X is (un)substituted C1-4 alkylene; Y is a bond, O, S, NH, C1-3 alkoxy, etc.; R1 is guanidino, (un)substituted imidazolylamino, (un)substituted pyridinylamino, (un)substituted benzimidazolylamino, etc.; R2 is H, halo and c1-6 alkyl; R3 is H, C1-6 alkyl, C3-10 carbocyclyl, etc.; R3a is H; R3R2a can be taken together to form (un)substituted C3-6 carbocyclyl and (un)substituted 3- to 6-membered heterocyclyl; R4 is H, C1-6 alkyl, C3-10 carbocyclyl, etc.; R5 is H, (un)substituted C1-6 alkyl, (un)substituted Ph, (un)substituted benzyl, etc.; dashed bonds are single and double bonds; and pharmaceutically acceptable salts thereof, are claimed. Example compound III was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their αVβ6 integrin antagonistic activity. From the assay, it was determined that compound III exhibited IC50 value of 1600 nM. The experimental process involved the reaction of tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate(cas: 445490-78-8).Name: tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

The Article related to indazole preparation integrin alpha v antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Name: tert-Butyl 7-(2-hydroxyethyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate

Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem